Site is Being Upgraded

 Molecular therapy for inflammation and arthritis: Monascin, a secondary metabolite derived from Monascus purpureus-fermented products, increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/March/2018, 1.47 pm

A glass of milk a day keeps stroke at bay: Milk product-based therapy for Stroke: Lactoferrin, a globular protein found abundantly in secretory fluids, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 21/March/2018, 12.57 pm
March 21, 2018
Amino acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  L-Serine, Epicatechin and Matrine (SEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/March/2018, 1.53 pm
March 21, 2018
Show all

Introduction: What they say

A study from Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany shows that “Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells.” This research paper was published, in the 17 July 2017 issue of the journal “Nature Medicine” [One of the best research journals in General Medicine with an I.Fs of 30.357], by Prof.Andreas Ramming, Rauber S and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:   Molecular therapy for inflammation and arthritis: Monascin, a secondary metabolite derived from Monascus purpureus-fermented products, increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes

[easy_payment currency=”USD”]


From the significance of the study to Public health relevance:

Given that: (1) Rheumatoid arthritis (RA) has caused 49,000 deaths globally in 2010; and it is likely that death due to RA may increase in the coming years; (2) RA approximately affects between 0.5% to 1% of adults in the developing world; (3) between 5 and 50 per 100, 000 people develop RA each year; (3) Women are three to five times more affected by RA than men; (4) most of the drugs that are in use today, to treat RA, treats only the symptoms, not the root cause of the disease; (5) RA is characterized by chronic joint pains; and (6) the global economic cost spent in the treatment of RA is enormous, there is an urgent need to find: (i) molecular mechanisms and the components involved in bio-pathways leading to RA; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free Natural product-based drug that alleviates not only alleviates pain, but also cures RA.


What is known?

Prof.Andreas Ramming‘s research team has recently shown that: (1) interleukin (IL)-9-producing type 2 innate lymphoid cells (ILC2s) as mediators of chronic inflammation; (2) the lack of IL-9 production culminates in: (a) defective ILC2 proliferation and activation of regulatory T (Treg) cells; (b) arthritis; (c) excessive cartilage destruction; and (d) bone loss; (3) treatment with IL-9 results in a) resolution of inflammation; and b) protection of bone; and (4) increased numbers of IL-9+ILC2s in joints and the circulation of patients, in remission stage of rheumatoid arthritis, suggesting that IL-9-mediated ILC2 activation is a method of treatment for chronic inflammation, such as arthritis, as it promotes resolution of inflammation rather than suppression of inflammatory mediators.


From research findings to Therapeutic opportunity:

This study suggests a small molecule-based therapy for inflammatory diseases, including arthritis. Monascin, by increasing the expression of its target gene, it may increase the expression of IL-9 and its down stream target genes. Thereby, it may: (1) increase the proliferation of ILC2s cells; (2) promote activation of Treg cells; (3) promote resolution of inflammation; (4) suppress cartilage destruction; (5) inhibit bone loss and strengthen bone structure; and (6) inhibit arthritis progression. Thus, pharmacological formulations encompassing Monascin or  its analogues, either alone or in combination with other drugs that are used to treat inflammatory diseases,” (fig 1), may be used to promote resolution of inflammation and inflammatory diseases, including arthritis.

Figure1. Mechanistic insights into how Monascin increases IL-9 levels, promotes proliferation/activation of ILC2s/Treg cells , enhances resolution of inflammation, stifles cartilage destruction and inhibits bone loss.

Figure 2. The chemical structure of Monascin. It is produced by Monascus purpureus-fermented products

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500#

Undisclosed mechanistic information: How Monascin increases IL-9 levels, activates ILC2 proliferation and regulatory T (Treg) cells, inhibits cartilage destruction, suppresses bone loss and improves arthritis.

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L.,  Molecular therapy for inflammation and arthritis: Monascin, a secondary metabolite derived from Monascus purpureus-fermented products, increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/March/2018, 1.47 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, kindly drop us a line at admin@genomediscovery.org

Comments are closed.